A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer

Clinical Lung Cancer

Volumn 12, Issue 3, 2011, Pages 161-165

  Horn, Leora ^a   Zhao, Zhiguo ^a   Sandler, Alan ^b   Johnson, David ^a   Shyr, Yu ^a   Wolff, Steven ^c   Devore, Russell F ^d   Laskin, Janessa ^e  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MEHARRY MEDICAL COLLEGE   (United States)

^d Tennessee Cancer Specialists   (United States)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Carboplatin and irinotecan; Clinical trial; Extensive stage; Small cell lung cancer

Indexed keywords

CARBOPLATIN; IRINOTECAN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADRENAL METASTASIS; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LIVER METASTASIS; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING; WEAKNESS;

EID: 79959601531     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.013     Document Type: Article

References (20)

1. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005; 366:1385-96. (Pubitemid 41443406)
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
3. Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:324S-39. (Pubitemid 47505212)
4. Clark R, Ihde DC. Small-cell lung cancer: treatment progress and prospects. Oncology (Williston Park) 1998; 12:647-58, discussion 661-3 (Pubitemid 128617860)
5. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine vs. cisplatin and etoposide vs. alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83:855-61.
6. Wolf M, Havemann K, Holle R, et al. Cisplatin/etoposide vs. ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. J Clin Oncol 1987; 5:1880-9. (Pubitemid 18010147)
7. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine vs. etoposide and cisplatin vs. alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10:282-91.
8. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposidecisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994; 5:601-7. (Pubitemid 24283096)
9. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85-91. (Pubitemid 34438898)
10. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27:2530-5.
11. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24: 2038-43. (Pubitemid 46622112)
12. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009; 27:3540-6.
13. Kano Y, Akutsu M, Suzuki K, et al. Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. Leuk Res 1993; 17:113-9. (Pubitemid 23075457)
14. Sohn JH, Choi HJ, Chang J, et al. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. Lung Cancer 2006; 54:365-70. (Pubitemid 44634144)
15. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187-205. (Pubitemid 46638957)
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10. (Pubitemid 19099520)
17. Kaplan EL, Meier P. Nonparametric observation for incomplete observation. J Am Stat Assoc 1958; 53:457-81.
18. Schmittel A, Fischer von Weikersthal L, Sebastian M, et al. A randomized phase II trial of irinotecan plus carboplatin vs. etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006; 17: 663-7.
19. Chen G, Huynh M, Fehrenbacher L, et al. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol 2009; 27:1401-4.
20. Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin vs. oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008; 26:4261-7.